Citations

Showing 10 of 108152 citations.

Repeat Length Polymorphism of the Serotonin Transporter Gene Influences Pulmonary Artery Pressure in Heart Failure
Olson, Thomas P. , Snyder, Eric M., Robert, Robert P, Johnson, Bruce D., Turner, Stephen T.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 20 | Issue: 4 | Pages: No page available

10.1096/fasebj.20.4.a403 Get It

Pulmonary hypertension is common in patients with heart failure (HF); however, for a given degree of left ventricular dysfunction, the range in pulmonary artery pressures (PAP) is large. Polymorphisms of a number of candidate genes have been implicated in contributing to smooth muscle dysfunction and remodeling of the pulmonary vasculature, including the serotonin transporter (5HTT) gene. Patients with HF may have mild tissue hypoxia, which may alter expression of 5HTT. This study examined the influence of a repeat length polymorphism in the promoter region of the 5HTT gene on differences in PAP in HF patients. Ninety HF patients (age=55±14yrs; LVEF=28±10%; NYHA=2.0±0.9) and 90 age and gender matched controls (CTL, age=51±15yrs; LVEF=63±7%) were recruited. Heart failure and CTL subjects were divided into 3 genotype groups, SS‐homozygotes for the short variant, LL‐homozygotes for the long variant and LS‐heterozygous condition. For both HF and CTL, SS n=20; LS n=41; LL n=29). PAP was calculated from the tricuspid regurgitant velocity. Age and gender did not differ between HF and CTL or among genotype groups. PAP was higher in HF compared to CTL (38.9±12.5 vs 27.7±8.2 mmHg, p<0.01, respectively) with a significant genotype effect in HF (SS=34.2±8.6 vs LS=38.2±11.4 vs LL=43.2±15.2 mmHg, p<0.05), but not in CTL. The HF group also demonstrated elevated left atrial diameter compared to CTL (HF 48.0±8.7 vs 32.8±4.8 mm, p<0.01, respectively) although no difference was seen within the HF group across genotypes. These results suggest that the LL variant of 5HTT is associated with elevated PAP in HF but not CTL. HL71478 and HL07111.
Incorporating elements of the musculoskeletal physical examination into the gross anatomy course
Jones, David, Capo, Jason, Milanese, Tia R, Schiefer, Terry K., Carmichael, Stephen W., Pawlina, Wojciech, Johnson, Rebecca L.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 20 | Issue: 4 | Pages: No page available

10.1096/fasebj.20.4.a451-c Get It

Objective The objective of this study was to introduce musculoskeletal physical examination skills in the gross anatomy course as a teaching tool and to evaluate medical students’ perceptions of this experience. Methods A list of 27 clinical examinations of the upper and lower limbs was generated from published core recommendations for undergraduate medical education. During gross anatomy laboratory sessions, teaching assistants (third year medical students) presented one or two of the clinical skills related to that day’s dissection to groups of 3–4 students at a time. The anatomic relationships tested by the clinical examinations were highlighted. One question on the laboratory examination at the end of the unit was an Objective Structured Clinical Examination (OSCE) station where students were given a clinical scenario and asked to demonstrate a physical examination that they would use in evaluating the patient. Following the upper and lower limb units, the students were given a Likert‐scale survey to evaluate their perceptions of the experience. Results Survey responses indicated that most students felt the physical examination demonstrations improved their understanding of the clinical significance of the related anatomy, increased their interest in and motivation to learn the material, and made the laboratory experience more enjoyable. Conclusions Introducing musculoskeletal physical examination skills in the gross anatomy course can be an effective way to emphasize the clinical significance of the anatomy, thereby enhancing students’ motivation to learn the material.
Purinergic Receptor Identification and Regulation of Voltage‐gated K + Channels in AML 14.3D10 Cells, a Human Eosinophil‐like Cell Line
Sandbulte, Jesse T., Bankers‐Fulbright, Jennifer L., Palmer, Melissa, Maniak, Peter J., O’Grady, Scott M.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 20 | Issue: 4 | Pages: No page available

10.1096/fasebj.20.4.a327-b Get It

The AML14 cell line and its AML14.3D10 subclone was established as a model cell system that exhibits phenotypic characteristics similar to that of human eosinophils. We investigated the effects of purinergic receptor stimulation on the physiological response of the AML 14.3D10 cell line to better evaluate its role as a suitable model for eosinophils using both molecular and functional approaches. Ca 2+ imaging experiments using Fura‐2 demonstrated the existence of purinergic receptors responsive to UTP (EC 50 of 8.9 x 10 −8 ), ATP γ‐s (EC 50 of 1.87 x 10 −7 ), and UDP (EC 50 of 7.44x 10 −6 ). Molecular identification of the purinergic receptor subtypes was confirmed by QRT‐PCR which demonstrated the presence of P2Y 1 , P2Y 2 , P2Y 4 , and P2Y 6 receptors. Ratio imaging experiments using the membrane potential sensitive indicator DiBAC‐3 showed that stimulation with UTP produced a membrane hyperpolarization of approximately 10 mV that returned to the original resting potential within 10 minutes after stimulation. Whole cell perforated patch clamp experiments using amphotericin B revealed the presence of voltage‐gated potassium channel currents that were stimulated following treatment with UTP. Analysis of mRNA by QRT‐PCR indicated the existence of several voltage‐gated potassium channel α subunits including, Kv1.2, Kv1.3, Kv1.4, and Kv1.6. Previous studies of Kv1.3 channel function in T‐lymphocytes showed that the channel was involved in activation and proliferation, suggesting the possibility of a similar role related to tumorogenesis in the AML 14.3D10 cell line.
PE-8: Relation Between Surgical Procedures, Chronic Intestinal Failure and Dependency on Parenteral Support
Iyer, Kirshore R., Mercer, David F. , Pfeffer, D., L, Brøsted Zimmermann, Berner‐Hansen, Mark , D', Limongelli, Mundi, Manpreet S. , D, L. Seidner

Mayo Clinic

Transplantation | June 21, 2021 | Volume: 105 | Issue: 7S | Pages: S33-S33

10.1097/01.tp.0000757704.78559.37 Get It

Abstract 181: What’s in the Black Box?: Describing Current Practice, Challenges, and Barriers of Cardiology and Palliative Care Collaboration
Mancarella, G, Wordingham, Sara E., Goodlin, Sara, Blume, Elizabeth D. , Cooper, Stephanie , Josephson, Richard , Cestoni, Abby, Hauptman, Paul J., Wells, Rachel D. , Dionne-Odom, James Nicholas , McIlvennan, Colleen Kelley , Goodlin, Sarah J. , Alexander, Karen P. , Maurer, Matthew, Hauptman, Paul J. , Kirkpatrick, James N , Bakitas, Marie , Swetz, Keith M.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | June 21, 2021 | Volume: 10 | Issue: suppl_3 | Pages: No page available

10.1161/circoutcomes.10.suppl_3.181 Get It

Background: Guidelines recommend involvement of palliative care (PC) for patients with cardiovascular (CV) disease and their families. Little is known about the current integration of PC and CV services. Research Objectives: Our national survey aimed to describe current practices and to identify benefits, challenges, and barriers with collaboration. Methods: Qualitative content analysis of open-response questions in an investigator-developed electronic survey study of CV and PC providers (MDs, NPs, PAs, and other allied health) using email listservs, social media, and crowdsourcing. Frequencies were tabulated using SAS statistical software. Results: Of 134 respondents, most were physicians (n=56, 57%) or advanced practice RNs or PAs (n=37, 28%), from 52 U.S. institutions, representing 33 states. The most common care for which PC was integrated were mechanical circulatory support, advanced heart failure, and heart transplantation; the least common care for which PC was integrated were TAVR, ECMO, and pulmonary hypertension. Integrated practice (n=80, 61%), PC identification of goals of care (n=20, 15%) and PC aid in patient/family communication (n=15, 11%) were the most commonly identified as positives in current practice. PC provider workforce (n=22, 16%), underutilization of PC referrals (n=20, 15%), late disease PC referral (n=19, 14%), and fundamental knowledge deficit of specialty scope (n=18, 14%) were most frequently identified as challenges. Other barriers specifically noted were underdeveloped health infrastructure and limited allocated resources (n=23,17%) and mis-/negative perception of services (n=15, 11%). Conclusion: PC and CV collaboration occurs for a high proportion of CV patients and is viewed as overwhelming positive, despite the challenges of limited PC specialists availability, underdeveloped healthcare infrastructure, limited understanding of specialty practice, and late referrals. Priorities includes increasing PC provider availability, expanding knowledge of PC services, educating providers on models of collaboration, and improving institutional support.
Abstract 127: Differences in Care Patterns, Health Status, and Outcomes of Atrial Fibrillation in Patients With and Without Diabetes: Findings From the ORBIT-AF Registry
Shrader, Peter, Thomas, Laine , Kowey, Peter R. , Singer, Daniel E. , Go, Alan S. , Piccini, Jonathan P. , Echouffo-Tcheugui, Justin B , Gersh, Bernard J. , Mahaffey, Kenneth W. , Hylek, Elaine M. , Peterson, Eric D. , Fonarow, Gregg C.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | June 21, 2021 | Volume: 10 | Issue: suppl_3 | Pages: No page available

10.1161/circoutcomes.10.suppl_3.127 Get It

Objective: Diabetes is a common among patients with atrial fibrillation (AF). However, little is known on the impact of diabetes on symptoms, health status, care and outcomes among AF patients. We assessed whether symptoms, health status, care and outcomes differ between AF patients with and without diabetes. Methods: This observational cohort study included 9,749 patients with AF from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation registry, a prospective, nationwide, multicenter outpatient registry of patients with incident and prevalent AF enrolled at 174 sites between June 2010 and August 2011. The outcomes were symptoms, health status, and AF treatment, as well as 2-year risks of death, readmission, thrombomebolic events, heart failure (HF) and AF progression. Results: Among AF patients; those with diabetes (29.5%) were younger and more likely to have hypertension, chronic kidney disease, HF, coronary heart disease, and stroke. Patients with diabetes had a lower Atrial Fibrillation Effects on Quality of Life score (80.6 [IQR: 62.5 - 92.6] vs. 82.4 [IQR: 67.6 -93.5]; P = 0.025), but a higher CHA 2 DS 2 -VASc score (5 [IQR: 4 - 6] vs. 4 [2 - 5]; P <0.0001) and were more likely to receive anticoagulation ( P <0.001). Diabetes was associated with higher mortality, with a greater overall (adjusted hazard ratio [aHR]: 1.63 [95% CI: 1.04-2.56] for age<70 vs. 1.25 [1.09-1.44] for age ≥70) and cardiovascular (2.20 [1.22-3.98] for age<70 vs. 1.24 [1.02-1.51] for age ≥70) mortality risks before age 70 years. Diabetes conferred a higher risk of non-cardiovascular (CV) death (1.29 [1.06-1.56]), sudden cardiac death (1.53 [1.04-2.26]), hospitalization (1.15 [1.09-1.22]), CV hospitalization (1.13 [1.05-1.22]) and non-CV and non-bleeding-related hospitalization (1.19 [1.10-1.30]); but no increase in risks of thromboembolic events, bleeding related hospitalization, new-onset HF, and AF progression. The use of oral anticoagulants (OAC) modifies the relation of diabetes and all-cause hospitalization, with a higher risk among those on OAC (1.21 [1.12-1.29]). Conclusions: Among patients with AF, diabetes was associated with worse AF symptoms and lower quality of life, as well an increased risk of death and hospitalizations, but not with the risk of thromboembolic or bleeding events.
Abstract 057: Understanding of Treatment Strategies Among Patients Newly Diagnosed With Atrial Fibrillation: Findings From SATELITTE
Kim, Sunghee , Pieper, Karen S. , Ezekowitz, Michael D. , Ansell, Jack , Berger, Peter B. , Reiffel, James A. , Singer, Daniel E. , Kowey, Peter R. , Piccini, Jonathan P. , O’Brien, Emily C. , Kaufman, Brystana G. , Fonarow, Gregg C. , Naccarelli, Gerald V. , Mahaffey, Kenneth W. , Chan, Paul S. , Allen, Larry A. , Freeman, James V. , Gersh, Bernard J. , Peterson, Eric D.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | June 21, 2021 | Volume: 10 | Issue: suppl_3 | Pages: No page available

10.1161/circoutcomes.10.suppl_3.057 Get It

Introduction: Patient understanding of available therapies for atrial fibrillation (AF) is foundational to shared medical decision making and long term medication adherence. Yet, there is a paucity of data regarding the extent to which patients newly diagnosed with AF in routine community practice understand their options. Hypotheses: 1) Understanding of warfarin, novel oral anticoagulants (NOAC), rhythm control therapy, cardioversion and radio frequency ablation changes little from baseline to 6 months and 2) treatment rates at 6 months are associated with patient understanding of therapies at baseline. Methods: We analyzed survey data from SATELLITE, a substudy of new-onset AF patients enrolled at 56 US sites participating in the ORBIT-AF registry. Patients were surveyed at the baseline and 6 month follow up clinic visit using Likert scales. Agreement between time points was assessed with the McNemar test, and the relationship between understanding and treatment was assessed only for the subset not on treatment at baseline. Results: Of 1000 patients enrolled in SATELLITE, 506 had 6-month survey data (data collection is continuing). Among these, the median age was 69.0 years (IQR 63.0 - 76.0) and 93.7% (474 of 506) were white. There was evidence of improvement in the self-reported understanding of warfarin and NOACs from baseline to 6 months, but not for rhythm control, ablation or cardioversion. The proportion reporting high understanding improved significantly for warfarin (p<.0001) and NOACs (p<.0001) from 47% (223 of 474) and 51% (245 of 481) at baseline to 60% (284 of 474) and 69% (332 of 481) at 6 months respectively (Figure 1). Patients with high understanding of the benefits of ablation (p=0.0005) and options for ablation (p=0.0093) at baseline were more likely to have this therapy at the 6 month follow up (N=590), but improved understanding was not associated with increased use of warfarin/NOACs (N=83) or rhythm control (N=444). Conclusions: Patients with new-onset AF had improved self-reported understanding of some treatment options over the first 6-months from diagnosis; however, factors other than patient understanding may influence AF treatments received at 6 months. Patient understanding of AF treatments remains suboptimal at 6 months, and our results suggest a need for ongoing patient education.
Abstract 029: Design, Safety and Effectiveness of Exercise Interventions in Patients With ICDs and CRT: a Systematic Review
Steinhaus, Daniel A. , Kramer, Daniel B. , Lubitz, Steven A. , Noseworthy, Peter A.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | June 21, 2021 | Volume: 10 | Issue: suppl_3 | Pages: No page available

10.1161/circoutcomes.10.suppl_3.029 Get It

Introduction: Exercise improves outcomes across a broad spectrum of cardiovascular disease. The optimal design, safety, and effectiveness of exercise-based interventions in ICD and CRT patients remain poorly understood. Methods: We performed a Pubmed search for clinical studies using the following search terms: “implantable cardioverter-defibrillators”; “ICD”; “cardiac resynchronization therapy”; “CRT”; and any one of the following: “activity”; “exercise”; “training”; or “rehabilitation”; from 1/1/2000 - 10/1/2015. Eligible studies were evaluated for study design features, measured endpoints, and reports of ICD shock rates. Results: From 649 articles, 75 abstracts met initial criteria from which 16 studies remained after full-text review: 56% randomized trials, 31% single-arm trials, 13% observational studies. A total of 2114 patients (median 52, range, 8 - 1053) were included. Exercise interventions varied widely in character and duration (mean days 82.6, range 23 - 168). VO2 max and other physiologic exercise performance measures were the most common primary endpoints (81%), with few studies evaluating clinical outcomes. Most studies (75%) showed statistically significant improvement in primary physiologic endpoints. ICD shocks were uncommon during active exercise intervention with only 7 shocks in 1248 patients. ICD shocks in follow-up were less common in patients receiving exercise intervention (16.9% v 25.6%, Figure). Conclusion: Exercise training in patients with ICDs and CRT appears safe and effective based on a small literature. Lack of consensus on design and both physiologic and clinical endpoints limit broader application to an important patient population.
Abstract 020: Stress and Achievement of Cardiovascular Health Metrics: The American Heart Association Life’s Simple 7 TM in African-Americans of the Jackson Heart Study
Slusser, Joshua P. , Roger, Véronique L. , Sims, Mario , Brewer, LaPrincess C. , Redmond, Nicole , Scott, Christopher G. , Chamberlain, Alanna M. , Djoussé, Luc , Patten, Christi A.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | June 21, 2021 | Volume: 10 | Issue: suppl_3 | Pages: No page available

10.1161/circoutcomes.10.suppl_3.020 Get It

Background: Cardiovascular disease (CVD) remains the leading cause of death for African-American (AA) adults. There is a low prevalence of ideal cardiovascular health (CVH) (as defined by the American Heart Association’s Life’s Simple 7 TM (LS7)), especially diet, physical activity and obesity among AAs placing them at a disproportionately high risk for CVD. The identification of psychosocial stress that may influence ideal CVH could assist in the development of more effective behavior change interventions among AAs. Objectives: The aim of this study is to examine the associations of multidimensional stressors (chronic stress, minor stressors, and major life events - MLEs) with the LS7 components (classified as poor, intermediate and ideal) in AAs. We hypothesize that stress is negatively associated with the likelihood of achievement of intermediate/ideal levels of the LS7 components and LS7 composite score after adjusting for traditional socio-demographic factors. Methods: Using the Jackson Heart Study (JHS), a cohort of AAs based in Jackson, Mississippi (n=4383), we conducted a cross-sectional analysis of the association of stress measures with LS7 components (smoking, diet, physical activity, body mass index, blood pressure, total cholesterol and glucose). This association was measured using logistic regression which assessed the odds ratios (OR, 95% confidence interval (CI)) of the achievement of intermediate/ideal levels of CVH with progressive adjustment for demographic, socioeconomic, behavioral and biomedical factors. A composite LS7 score was calculated [range 0-14; categorized as 0 to 6 (poor), 7 to 8 (intermediate) and 9 to 14 (ideal)]. We also constructed a cumulative stress score as a summation of tertiles of each stress measure (range 3-9). Results: Fewer participants achieved intermediate or ideal CVH for the LS7 components including diet (39%), physical activity (51%) and BMI (47%). Higher chronic stress and minor stressors scores were associated a decreased likelihood of achievement of ideal/intermediate levels for smoking [OR 0.80; 95% CI 0.73-0.88 and OR 0.84; 95% CI 0.75-0.94, respectively). Higher MLE scores were associated decreased likelihood of achievement of ideal/intermediate levels for smoking (OR 0.84; 95% CI 0.76-0.92) and glucose (OR 0.90; 95% CI 0.82-0.98). Those with higher minor stressors and MLE scores were less likely to achieve intermediate or ideal LS7 composite score categories (OR 0.89; 95% CI 0.81-0.97 and OR 0.91; 95% CI 0.84-0.98, respectively). There was no statistically significant association between LS7 composite scores and cumulative stress scores. Conclusions: Our results suggest that key stress measures may contribute adversely to CVH among AAs. These findings provide support for future lifestyle interventions which integrate a focus on alleviating stressors in this high risk population to improve CVH.
Abstract 019: Real-World Use of Sacubitril/ Valsartan in Heart Failure in the First Year Following FDA Approval
Sangaralingham, Lindsey R. , Sangaralingham, S. Jeson , Houten, Holly K. Van , Shah, Nilay D. , Adigun, Rosalyn , Sangaralingham, S. Jeson , Dunlay, Shannon M.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | June 21, 2021 | Volume: 10 | Issue: suppl_3 | Pages: No page available

10.1161/circoutcomes.10.suppl_3.019 Get It

Background: In July 2015, the FDA approved the use of sacubitril/ valsartan in patients with heart failure (HF) and reduced ejection fraction. It was shown in a large clinical trial to reduce the risk of both hospitalization and death compared with enalapril, and has since received a class I recommendation for use in the 2016 ACC/ AHA HF guidelines. However, the use of sacubitril/ valsartan in a clinical practice has not been described. We aimed to assess the uptake and cost of sacubitril/ valsartan in its first year following FDA approval. Methods: Using a large U.S. insurance database, we identified privately insured and Medicare Advantage (MA) patients who filled a first prescription for sacubitril/ valsartan between July 1, 2015 and July 31, 2016. We restricted to persons with medical and pharmacy enrollment for 6 months prior to first fill. For reference, we identified all individuals with a diagnosis of HF on a billing claim (ICD9 428.X or ICD-10 I50.X) in the same time period. Results: There were 314,410 individuals with a diagnosis of HF in the study period. In total, 972 filled a new prescription for sacubitril/ valsartan, and the number of new users steadily increased over time (Figure). The mean age of sacubitril/ valsartan users was 68.1±12.3 years, 32.5% were women, 61.1% were white, and 77% were enrolled in MA plans. Most prescribing clinicians were cardiologists (82.5%). A majority of prescription costs were covered by the health plan (mean $324.05, median $335.38, interquartile range [IQR] $266.56-$370.10). Out-of-pocket (OOP) costs per 30-day prescription filled were variable (mean $101.53, median $45.00, IQR $7.40-$97.49), and were similar in beneficiaries enrolled in MA and commercial plans. By comparison, median OOP costs were $2-4 for lisinopril, losartan, carvedilol, and spironolactone per 30-day prescription. Discussion: These finding suggest that the uptake of sacubitril/ valsartan has been slow in the first year after FDA approval. While the majority of prescription costs are covered by the health plan, OOP costs are still much higher than other guideline-recommended HF medications. Further studies are needed to determine if uptake of sacubril/ valsartan continues to rise and if the higher prescription cost is associated with lower downstream costs of hospitalization and mortality benefit.